REG - ReNeuron Group plc - Directorate and Executive Changes

ReNeuronAnnouncement

14/09/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220914:nRSN3423Za&default-theme=true

RNS Number : 3423Z  ReNeuron Group plc  14 September 2022

 

ReNeuron Group plc

("ReNeuron" or the "Company" or the "Group")

 

Directorate and Executive Changes

Appointment of Chief Financial Officer and Chief Business Officer

 

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived
exosome technologies, announces the appointment of John Hawkins, ACA, as Chief
Financial Officer ('CFO') and ReNeuron Board member with immediate effect. The
Group is also pleased to announce that Simon Dew will be joining the Executive
Team as Chief Business Officer ('CBO').

 

Mr. Hawkins joined ReNeuron in October 2014 as Financial Controller and was
also appointed Company Secretary in June 2021. Mr Hawkins is an experienced
finance professional with a breadth of experience gained within a variety of
businesses, from large PLCs to family-owned SMEs. Mr Hawkins graduated from
university with a 1st class honours degree in industrial chemistry and started
his career with KPMG, where he qualified as a Chartered Accountant and worked
for the initial part of his career.

 

Mr. Dew is a senior healthcare executive with extensive experience in Business
Development and Corporate Strategy. His career spans working at SmithKline
Beecham, IQVIA, Astellas Pharma, Gyroscope and more recently exosomes company
Evox Therapeutics, where he was responsible for leading two transformational
partnership deals with global pharmaceutical companies.

 

Additionally, the Group is making changes to the Executive team. With
immediate effect, Dr. Randolph Corteling assumes the role of Chief Scientific
Officer ('CSO') with Prof. Stefano Pluchino moving to the role of Chair of the
Scientific Advisory Board, continuing to combine working with ReNeuron and his
academic work in Exosomes and Regenerative Neuroimmunology at the University
of Cambridge. Suzanne Hancock, currently Head of Operations, who has worked
with the Group since 2017, moves to the position of Chief Operations Officer
('COO').

 

Iain Ross, Non-Executive Chairman, commented "I am delighted to announce John
Hawkins' appointment as CFO and a director of the Company and also to welcome
Simon Dew as member of the Executive team. I believe under Catherine's
leadership we have a strong executive team in place to execute our plans."

 

Catherine Isted, Chief Executive Officer, commented: "I am delighted John has
accepted the position of CFO. He has been a key part of the team redefining
the operational and strategic focus of the Group and his extensive knowledge
of the business and tireless work ethic have been invaluable especially in
this period of transition.

 

"The appointment of Simon Dew as CBO will be a key role in the new ReNeuron
Executive team to maximise the opportunity we see ahead of us in the field and
to accelerate our partnership opportunities. We are delighted to have been
able to attract a candidate of such high calibre and experience, especially in
the field of exosomes, to join the Group.

 

"With the other Executive changes announced today, I believe we have the right
team in place to deliver on the full potential that our customisable Exosomes
platform has to offer to biotech and pharma partners and ultimately deliver
value to our shareholders as we build ReNeuron into the sustainable growing
and commercially validated business we know it can become."

 

The following information is disclosed in respect of John Hawkins pursuant to
Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

 

The names of all companies and partnerships of which John Michael Hawkins,
aged 56, has been a director or partner at any time in the previous five years
are set out below:

 

 Current directorships or partnerships  Previous directorships or partnerships
 86 Cathedral Road Rtm Company Limited  N/A

( )

John Hawkins holds options over 340,000 ordinary shares of ReNeuron. Save as
set out in this announcement, there are no further details to be disclosed
under Rule 17 or Schedule 2(g) of the AIM Rules for Companies in respect of
John Hawkins.

 

 

 
ENDS

 

The person responsible for arranging for the release of this announcement on
behalf of the Company is

Catherine Isted, Chief Executive Officer.

 

 

Contacts:

 

 ReNeuron Group plc                                www.reneuron.com/investors (http://www.reneuron.com/investors)
 Iain Ross, Chairman                               Via Walbrook PR
 Catherine Isted, Chief Executive Officer

 Liberum Capital Limited (NOMAD and Joint Broker)  +44 (0)20 3100 2000

 Phil Walker (Investment Banking)

 Richard Lindley (Investment Banking)

 Ben Cryer (Investment Banking)

 Allenby Capital Limited (Joint Broker)            +44 (0)20 3328 5656
 James Reeve / George Payne (Corporate Finance)
 Stefano Aquilino (Sales & Corporate Broking)

 Walbrook PR (Media & Investor Relations)          +44 (0)20 7933 8780 or reneuron@walbrookpr.com
 Paul McManus / Alice Woodings                     +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About ReNeuron

ReNeuron is a UK based leader in Proprietary Stem Cell derived Exosome
Technologies company, harnessing its unique stem cell technologies to develop
'off the shelf' treatments for diseases with significant unmet needs.

 

ReNeuron's stem cell derived proprietary Exosome Technology platform offers a
delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins,
small molecules and genes. The Group has a growing number of partner
collaborations with Global Pharma, Biotech and academic partners in this
fast-expanding area of scientific and commercial interest. ReNeuron also has
the ability, through its conditionally immortalised induced pluripotent stem
cell (iPSC) platform, to make allogeneic tissue cells of choice and has the
potential to produce exosomes with tissue specific targeting ability.

 

The Group has out-licenced its CTX Programme for stroke disability and hRPC
programme in retinitis pigmentosa to Fosun in China and is looking to
out-licence both these programmes in other territories.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUOVNRURUKAAR